Cellular Biology |
From the Cardiovascular Research Group, Temple University School of Medicine, Philadelphia, Pa.
Correspondence to Dr Steven Houser, Cardiovascular Research Group, Temple University School of Medicine, 3400 North Broad St, Philadelphia, PA 19140. E-mail srhouser{at}unix.temple.edu
| Abstract |
|---|
|
|
|---|
Key Words: L-type calcium channel heart failure left ventricle assist device PKA-dependent phosphorylation
| Introduction |
|---|
|
|
|---|
Alterations in Ca2+ handling are thought to be centrally involved in heart failure contractile dysfunction.7 Reduced SR Ca2+ storage and release8,9 and slow removal of Ca2+ from the cytoplasm1,10 appear to be contributors to the reduced rate and magnitude of force generation and prolongation of systole that are key features of the failing human heart. Reduction in the abundance and activity of the sarcoplasmic reticulum (SR) Ca2+ ATPase (SERCa) and increased abundance and/or activity of the sarcolemmal Na+-Ca2+ exchanger (NCX) appear to be critical contributors to the abnormal Ca2+ handling in the failing human heart.7
The blunted contractile reserve of the failing heart is thought to involve alterations in the abundance and activity of molecules that participate in the adrenergic signaling cascade. Activation of this signaling pathway increases contractility in the normal heart by phosphorylation of Ca2+ regulatory proteins.2,3,11 Normalization of the abundance of some of these proteins has been observed in LVAD-supported human hearts12 and is likely to be involved in the associated restitution of contractility and adrenergic responsiveness.4,12
Ca2+ influx through the LTCC is essential for triggering the SR Ca2+ release (excitation-contraction coupling) that determines the rate and magnitude of contraction and is the major source of Ca2+ to load the SR.13 Therefore, abnormalities in LTCC density or regulation should have profound effects on cardiac function. Although most previous studies have not found substantial changes in whole-cell L-type calcium current (ICa,L) density in heart failure,14,15 two recent investigations suggest that LTCC density may be reduced16 and that phosphorylation state17 may be increased. The present study was designed to explore these possibilities.
The objectives of the present experiments were to determine (1) if the density and properties of ICa,L are altered in F-HVMs; (2) by what mechanisms the regulation of ICa,L by ß-adrenergic agonists is abnormal in F-HVMs; and (3) if LVAD support of the failing heart reverses LTCC abnormalities. Our results suggest that LTCC density is reduced in F-HVMs but basal ICa,L current density is maintained by increasing LTCC phosphorylation and that these alterations are partially reversed with LVAD support. These findings suggest that a reduction in LTCC density and aberrant channel regulation are centrally involved in the defective Ca2+ homeostasis of the F-HVMs and that reversing these defects is associated with recovery toward normal myocyte contractility.
| Materials and Methods |
|---|
|
|
|---|
|
Ca2+ Current Measurement
Whole-cell Ca2+ currents (ICa,L) were measured in Na+- and K+-free solutions at 37°C using techniques described in detail previously19 (see online data supplement). To define the ICa,L-voltage relationship, the membrane potential was held at -70 mV and then depolarized in 10-mV increments. Myocytes were then exposed to various activators of the Ca2+ current (described below) and the effects were monitored by recording ICa,L during steps to +10 mV. When effects were stable, the ICa,L-voltage relationship was again determined. Only myocytes with minimal (<10%) rundown of ICa, L were included in the data sets.
Pharmacology
To activate protein kinase A (PKA) signaling pathways, myocytes were exposed to the nonselective ß-adrenergic receptor agonist ISO (1 µmol/L, Sigma). PKA was also activated with a nonhydrolyzable form of cAMP (dibutyryl-cAMP [db-cAMP], 10 µmol/L, Sigma) in the pipette solution. Some cells were also exposed to the dihydropyridine Ca2+ channel agonist Bay K 8644 (1 µmol/L, Sigma) to increase ICa,L independently of PKA.20 These concentrations were used because they produced maximal stable effects on ICa,L in preliminary experiments. The phosphatase inhibitor Okadaic acid (OA, Calbiochem, 1 µmol/L in pipette) and phosphatase 2A1 (10 U/mL in pipette, Sigma) were tested as described.
Statistics
Data in the text and tables are reported as mean±SEM. Paired and unpaired t tests were used to compare the effects of drugs before and after their applications. Differences among multiple groups were tested with ANOVA or ANOVA for repeated measures with SAS (SAS Institute Inc). A value of P=0.05 was considered significant.
| Results and Discussion |
|---|
|
|
|---|
|
|
The most significant difference in ICa,L characteristics under basal conditions was that the voltage dependence of ICa,L activation (d
) was more negative in F- and LVAD- versus NF-HVMs (Figure 1A and 1B). The membrane potentials at which one-half of the maximal ICa, L was activated (V0.5) in F, LVAD, and NF were -7.18±1.4, -7.0±0.9, and 0.46±1.1 mV in F-, LVAD-, and NF-HVMs, respectively.
A negative shift in the voltage dependence of ICa,L activation can be induced by PKA-mediated phosphorylation (usually through ß-adrenergic signaling pathway) of the LTCC complex.22 Therefore, one interpretation of our finding is that the basal level of LTCC phosphorylation is increased in F- and LVAD- versus NF-HVMs. This idea is consistent with the results of a recent study that found an increased open probability of single LTCCs in failing human myocytes, a behavior caused by channel phosphorylation.17 Because the whole-cell current density (I) is determined by the product of the LTCC density (N), open probability (Po), and single channel current (i), ie, I=N · Po · i,23 our results would suggest that in F-HVMs, a reduced LTCC density (N) is offset by an increase in Po so that the basal ICa,L density (I) is maintained.
Effects of ISO on Ca2+ Current
If LTCC phosphorylation state is increased in F-HVMs, then the effects of agents that promote PKA-mediated phosphorylation of the LTCC in F-HVMs should be less than in NF-HVMs, ie, a smaller percent change in ICa,L after the application of PKA activators (ISO).24 ISO increased ICa,L in every group of myocytes studied (Figure 2). However, the effects on peak ICa,L density were significantly smaller in F- versus NF- and LVAD-HVMs (Figures 2 and 3). ISO also caused a significant acceleration of the kinetics of ICa,L inactivation in NF- and LVAD-HVMs but not in F-HVMs (Figure 4), consistent with the larger increases in ICa,L in these myocytes.23,25 ISO also caused the voltage dependence of ICa,L activation to shift to more negative potentials in NF- and LVAD-HVMs,22 but had no significant effect in F-HVMs (Figure 3). It is noteworthy that the voltage dependence of ICa,L activation was already shifted to the left in F-HVMs under our basal conditions, and after ISO exposure, there was no significant further shift. After ISO, there were no significant differences in V0.5 between any groups (Figure 3). These results suggest that there was an equivalent level of LTCC phosphorylation after ISO in all myocytes. Our observations also suggest that the blunted response to ß-adrenergic agonists in failing myocytes26 involves the persistent phosphorylation of PKA target proteins under our basal conditions.
|
|
|
Effects of db-cAMP
A common explanation for reduced adrenergic effects in heart failure is that adrenergic signaling abnormalities produce reduced cytosolic cAMP concentration and thus reduced phosphorylation of PKA target proteins.2,3 Abnormal adrenergic signaling in human heart failure is well supported by many studies and is thought to involve changes in ß-receptor density and subtypes, G-protein abundance and subtypes,27,28 phosphatase abundance,29 and activity of ß-adrenergic receptor kinase 1.30 In general, these signaling alterations would reduce phosphorylation of PKA target proteins, and in this regard, there is evidence for reduced phosphorylation of both phospholamban29 and troponin-I31 in the failing human heart.
However, there is also evidence that the ryanodine receptor (RYR, also known as the Ca2+ release channel)32 and the LTCC17 are hyperphosphorylated in human heart failure. If all of these results are correct, then it would indicate that protein function is differentially regulated in specific subcellular microdomains such that the average levels of cytoplasmic cAMP does not dictate the level of PKA-mediated phosphorylation in specific regions of the cell. The LTCC is localized near the RYR,33 to optimize Ca2+-induced Ca2+ release from the SR. Given this close spatial proximity, it would not be surprising if regulation of RYR and the LTCC were coordinated, and both molecules were in a hyperphosphorylated state in the failing heart.
To determine if the reduced effects of ISO on ICa,L in F-HVMs results from either defective cAMP generation that limits LTCC phosphorylation or from increased basal LTCC phosphorylation, myocytes were exposed to db-cAMP. Peak ICa,L was significantly greater than control in the presence of db-cAMP in all 3 groups of myocytes (Figure 5). However, db-cAMP effects on peak ICa,L in F-HVMs were significantly smaller than in either NF- or LVAD-HVMs (Figure 5C). The fact that the voltage dependence of ICa,L activation was not different in any of the 3 groups after db-cAMP (Figure 5E) is consistent with a similar phosphorylation state of the LTCC. These results support the idea that a larger than normal fraction of the LTCC is phosphorylated under basal conditions in failing human myocytes. It is noteworthy that this idea is difficult to test directly with biochemical techniques because the phosphorylation state of the LTCC in cardiac myocytes is not easily measured.34
|
Effects of BAY K8644
If the LTCC density and phosphorylation state are identical in our 3 populations of myocytes, then BAY K8644, which increases Po of the LTCC independent of PKA-dependent signaling pathways,20 should have equivalent effects on ICa,L in all groups. If LTCC density is reduced but the phosphorylation state and Po are increased in F-HVMs versus NF- and LVAD-HVMs, then BAY K8644 should have a smaller effect in F-HVMs. We found that BAY K8644 increased ICa, L in all myocytes; however, the magnitude of the effect was significantly smaller in F- versus NF- and LVAD-HVMs (Figure 5). These results are also consistent with the idea that the number of LTCCs is reduced in failing myocytes and that there is an increase in channel phosphorylation. Our results also show that these changes are largely reversed in LVAD-HVMs.
Effect of Okadaic Acid and Phosphatase 2A
Alterations in the basal phosphorylation state of LTCC are likely to reflect changes in the balance of activities of PKA and phosphatases. An increase in basal LTCC phosphorylation could result from an increased activity of PKA and/or a decreased activity of phosphatases. In a small series of experiments to begin to explore these issues, we found that there was no significant change in peak ICa,L when NF- and F-HVMs were exposed to the PKA inhibitors H-89 (in NF [n=4], control versus H-89: -6.78±0.86 versus 6.51±0.50 pA/pF; in F [n=3], control versus H-89: -7.16±0.74 versus 6.93±0.64 pA/pF) and Rp-cAMP (in F cells [n=5], control versus Rp-cAMP: 6.45±0.61 versus 6.76±0.82 pA/pF). Schroder et al17 have suggested that the endogenous phosphatase activity associated with LTCCs is decreased in failing HVMs. We found that the phosphatase inhibitor OA increased ICa,L in NF-HVMs (control [n=5] -6.34±0.43 versus OA [n=3] -11.78±0.58 pA/pF; P<0.05) by 85.6% but had no significant effect in F-HVMs (control [n=3] -9.31±2.11 versus OA [n=3] -9.39±3.92 pA/pF). Next, we examined the effects of PP2A, which has been shown to dephosphorylate LTCCs in a previous study.35 PP2A caused a 35% decrease in the peak ICa,L in F-HVMs (Control [n=4, N=2] versus PP2A [n=4, N=2]: -11.32±0.66 versus -7.34±1.23 pA/pF; P<0.05), whereas PP2A did not significantly change ICa,L in NF-HVMs (Control [n=5, N=2] versus PP2A [n=5, N=2]: -6.22±0.38 versus -7.28±1.09 pA/pF; P<0.05). It is important to point out that these more mechanistic experiments were performed in a smaller number of myocytes than in those experiments shown in Figures 1 through 5 and these results will need to be confirmed in a broader sample set. Nevertheless, these findings suggest that in NF-HVMs (under our basal conditions), the endogenous phosphatase activity outweighs a low level of endogenous PKA activity so that there is little phosphorylation of LTCCs. In the few F-HVMs that were studied, there appears to be little or no endogenous phosphatase activity and the addition of PP2A is required to reduce ICa,L. These results suggest that under our conditions the basal phosphorylation state of LTCCs is largely determined by activity of protein phosphatases.
Evidence for Hyperphosphorylation of PKA Target Proteins in Human Heart Failure
Schroder et al17 first reported that the biophysical properties of single LTCCs from failing human hearts are consistent with a higher than normal phosphorylation state (higher open probability). One of the limitations of this study is that LTCCs in the t-tubules were not studied. Our experiments using whole-cell techniques suggest that the phosphorylation state of the entire population of LTCCs is likely to be increased in human heart failure. Our results are also consistent with a recent study in failing canine myocytes,16 suggesting that reduced LTCC density is a general feature of failing myocardium. Our results are also in general agreement with those studies of RYR in failing human heart.32 These composite results suggest that the cellular microdomain between the t-tubule and the junctional SR can locally regulate the phosphorylation of PKA target proteins and that the phosphorylation state of these molecules is increased in failing human ventricular myocytes. We further suggest that a decreased activity of phosphatases in this microdomain may be responsible for our results.
As discussed earlier, there is also good evidence for decreased phosphorylation of phospholamban36 and troponin-I (Tn-I) in the failing human heart.31,36,37 Reduced PLB and Tn-I phosphorylation are thought to be partly responsible for the depressed SR function and increased myofilament Ca2+ binding affinity that have been observed in the failing heart.31,36,37 The bases of uncoordinated phosphorylation states of PKA target proteins in human heart failure are yet to be resolved. High tonic levels of circulating catecholamines in end stage human heart failure38 would predispose toward increased phosphorylation of PKA target proteins whereas adrenergic signaling defects would blunt the effects of this chronically heightened adrenergic state29 and predispose toward a lower phosphorylation state. We speculate that different portions of the same myocyte can respond to persistent ß-adrenergic activation in different fashions by locally regulating the activity of PKA and phosphatases rather than by changing the global concentration of cAMP.
We provide 3 independent observations consistent with an increased phosphorylation state of LTCC in F- versus NF-HVMs. These are as follows: (1) the leftward shift of ICa,L-V curves in F- versus NF-HVMs under basal condition but similar ICa,L-V curves after ISO and db-cAMP application; (2) smaller effects of isoproterenol, db-cAMP, and Bay K8644 on ICa, L in F-HVMs; and (3) a decrease in ICa,L by PP2A in F-HVMs. It is important to point out that other factors are likely to be involved in the differences in ICa,L observed in our experiments. The fact that LVAD-HVMs respond to ISO like NF-HVMs yet their basal GCa,L-V relationship is shifted to the left like F-HVMs attests to this idea. Other factors that will need to be considered to resolve these issues include the types of accessory (ß) LTCC subunits,34 different isoforms of the
1c subunit of LTCC,43 and the possibility that different phosphorylation sites are responsible for regulating different properties39 of LTCC, like Po and the voltage-dependence of activation.
Evidence for a Decreased Density of L-Type Ca2+ Channels in Failing Ventricular Myocytes
The density of L-type Ca2+ channels can be directly studied in intact myocytes with voltage clamp techniques. Most of the previous studies using these assays have shown that there is either no change or a small decrease in the LTCC current density in the hypertrophied and failing myocytes (see review by Mukherjee et al14). However, one of these studies recently showed that although ICa,L density was unchanged in failing canine myocytes the charge movement associated with channel activation (an assay for the total number of channels) was significantly reduced,16 in agreement with our present observations in human myocytes.
Changes in LTCC density in the failing human heart have also been evaluated using biochemical and molecular techniques. These studies have shown that the mRNA abundance of the
1c subunit of the LTCC is either unchanged40,41 or reduced in the failing heart.42 Quantifying LTCC number with the dihydropyridine binding method, Rasmussen et al40 found that the number of DHP binding sites was unchanged in failing hearts, whereas Takahashi et al42 found the
1c subunit decreased in abundance at both the mRNA and protein (DHP binding sites) level. These studies generally support our contention that the density of LTCC is decreased in human heart failure. It is important to keep in mind however that extrapolation of mRNA and DHP binding data to the functional status of LTCCs in intact cells should be done cautiously because it is known that LTCC accessory proteins,43 channel modifications (phosphorylation is one example), and localization can alter the function of the LTCC without requiring a change in mRNA or DHP binding.
Normalization of LTCCs in LVAD-HVMs
Recently, we4 and others6 have shown that many of the abnormalities in cardiac contractility and gene expression in the failing human heart are at least partially reversed if these hearts are supported with mechanical assist devices. The present results suggest that increases in the sarcolemmal density of LTCCs and a reduction in the level of basal channel phosphorylation are involved in the improved basal contractility and improved ß-adrenergic responsiveness observed in the LVAD-supported heart.
Functional Significance of Reduced LTCC Density With Increased Phosphorylation
The mechanisms responsible for increased LTCC phosphorylation in F-HVMs appear to involve alterations in phosphatase activity. These LTCC alterations have predictable effects on the function of failing heart. A reduction in the density of LTCC should eventually produce alterations in EC coupling.44 Defective EC coupling would reduce the amount of Ca2+ released from the SR and contribute to systolic dysfunction. A higher level of basal channel phosphorylation would also limit the ability of additional ß-adrenergic activation to further augment the ICa,L. This would explain the inability of ß-agonists to rescue defects in EC coupling in animal models of CHF.44 Because ß-agonist-induced augmentation of the ICa,L is largely responsible for enhancing SR Ca2+ loading in normal myocytes,19 increased basal phosphorylation of LTCC is likely to be involved in the blunted inotropic effects of adrenergic stimulation in the failing human heart.
Limitations
All studies that utilize tissues and myocytes from end stage failing human hearts are limited by the fact that there is tremendous patient-to-patient variability in disease etiology and treatment (and a host of other factors). It is also important to point out that our nonfailing (control) group may not reflect normal human tissue. Therefore, all studies of this type need to be interpreted cautiously, with results used to point the way to more mechanistic studies under more controlled conditions in appropriate model systems. Finally, our experiments that examined the roles of PKA and PP2A in altered LTCC properties were performed in a small number of myocytes from a few hearts. The clues provided by these experiments will need to be confirmed in an expanded study.
Conclusion
Our results suggest that previously unrecognized alterations in the density and regulation of the L-type Ca2+ channel contribute to the abnormal contractility and blunted adrenergic responsiveness of the failing human heart.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received April 18, 2002; revision received August 7, 2002; accepted August 7, 2002.
| References |
|---|
|
|
|---|
q signaling after left ventricular assist device support in failing human hearts. Cardiovasc Res. 2000; 45: 883888.
in human hearts with dilated but not ischemic cardiomyopathy. Circulation. 1990; 82: 12491265.This article has been cited by other articles:
![]() |
X. Chen, X. Zhang, D. M. Harris, V. Piacentino III, R. M. Berretta, K. B. Margulies, and S. R. Houser Reduced effects of BAY K 8644 on L-type Ca2+ current in failing human cardiac myocytes are related to abnormal adrenergic regulation Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2257 - H2267. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Miriyala, T. Nguyen, D. T. Yue, and H. M. Colecraft Role of CaV{beta} Subunits, and Lack of Functional Reserve, in Protein Kinase A Modulation of Cardiac CaV1.2 Channels Circ. Res., April 11, 2008; 102(7): e54 - e64. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ikeda, M. Hoshijima, and K. R. Chien Toward Biologically Targeted Therapy of Calcium Cycling Defects in Heart Failure Physiology, February 1, 2008; 23(1): 6 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Bito, F. R. Heinzel, L. Biesmans, G. Antoons, and K. R. Sipido Crosstalk between L-type Ca2+ channels and the sarcoplasmic reticulum: alterations during cardiac remodelling Cardiovasc Res, January 15, 2008; 77(2): 315 - 324. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. P. Collis, S. Srivastava, W. A. Coetzee, and M. Artman beta2-Adrenergic receptor agonists stimulate L-type calcium current independent of PKA in newborn rabbit ventricular myocytes Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2826 - H2835. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Brette and C. Orchard Resurgence of Cardiac T-Tubule Research Physiology, June 1, 2007; 22(3): 167 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kawai, T. Kawai, J. T. Sambol, D.-Z. Xu, Z. Yuan, F. J. Caputo, C. D. Badami, E. A. Deitch, and A. Yatani Cellular mechanisms of burn-related changes in contractility and its prevention by mesenteric lymph ligation Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2475 - H2484. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-k. Wei, A. M. Ruknudin, M. Shou, J. M. McCurley, S. U. Hanlon, E. Elgin, D. H. Schulze, and M. C.P. Haigney Muscarinic Modulation of the Sodium-Calcium Exchanger in Heart Failure Circulation, March 13, 2007; 115(10): 1225 - 1233. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Hall, E. J. Birks, S. Grindle, M. E. Cullen, P. J. Barton, J. E. Rider, S. Lee, S. Harwalker, A. Mariash, N. Adhikari, et al. Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy Eur. Heart J., March 1, 2007; 28(5): 613 - 627. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Antoons, P. G. A. Volders, T. Stankovicova, V. Bito, M. Stengl, M. A. Vos, and K. R. Sipido Window Ca2+ current and its modulation by Ca2+ release in hypertrophied cardiac myocytes from dogs with chronic atrioventricular block J. Physiol., February 15, 2007; 579(1): 147 - 160. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Bers Altered Cardiac Myocyte Ca Regulation In Heart Failure. Physiology, December 1, 2006; 21(6): 380 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Endo, M. Miura, M. Hirose, J. Takahashi, M. Nakano, Y. Wakayama, Y. Sugai, Y. Kagaya, J. Watanabe, K. Shirato, et al. Reduced Inotropic Effect of Nifekalant in Failing Hearts in Rats J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1102 - 1107. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Mills, H. Kubo, D. M. Harris, R. M. Berretta, V. Piacentino III, and S. R. Houser Phosphorylation of phospholamban at threonine-17 reduces cardiac adrenergic contractile responsiveness in chronic pressure overload-induced hypertrophy Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H61 - H70. |